Table 1.
Main characteristics of patients with advanced LC who were diagnosed between 1 January 2011 and 31 December 2021 and received first-line SACT.
| Number of Patients | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011-2012 | 2013-2014 | 2015-2016 | 2017-2018 | 2019 | 2020 | 2021 | Total | |||||||||
| Patients with new LC diagnosis (n) | 6,507 | 6,628 | 6,556 | 6,642 | 3,232 | 2,885 | 2,966 | 35,416 | ||||||||
| Male (n, % of LC patients) | 4,153 | 63.82% | 4,066 | 61.35% | 4,023 | 61.36% | 4,010 | 60.37% | 1,816 | 56.19% | 1,687 | 58.47% | 1,702 | 57.38% | 21,457 | 60.59% |
| Female (n, % of LC patients) | 2,354 | 36.18% | 2,562 | 38.65% | 2,533 | 38.64% | 2,632 | 39.63% | 1,416 | 43.81% | 1,198 | 41.53% | 1,264 | 42.62% | 13,959 | 39.41% |
| Mean age at diagnosis (y, mean ±SD) | 62.09 | ±8.02 | 62.92 | ±8.09 | 63.79 | ±7.75 | 64.41 | ±7.90 | 65.45 | ±8.13 | 65.58 | ±8.18 | 66.29 | ±8.00 | 63.89 | ±7.98 |
| Male (y, mean ±SD) | 61.70 | ±8.46 | 62.24 | ±8.28 | 62.92 | ±8.06 | 64.12 | ±7.79 | 64.93 | ±7.63 | 64.98 | ±8.11 | 65.81 | ±8.04 | 63.46 | ±8.08 |
| Female (y, mean ±SD) | 61.95 | ±8.19 | 62.66 | ±8.17 | 63.45 | ±7.88 | 64.30 | ±7.86 | 65.22 | ±7.92 | 65.33 | ±8.16 | 66.08 | ±8.02 | 63.72 | ±8.03 |
| Age groups | ||||||||||||||||
| 20-49 | 421 | 6.47% | 379 | 5.72% | 315 | 4.80% | 264 | 3.97% | 107 | 3.31% | 118 | 4.09% | 92 | 3.10% | 1,696 | 4.79% |
| 50-59 | 2,083 | 32.01% | 1,900 | 28.67% | 1,530 | 23.34% | 1,381 | 20.79% | 594 | 18.38% | 504 | 17.47% | 470 | 15.85% | 8,462 | 23.89% |
| 60-69 | 2,795 | 42.95% | 2,977 | 44.92% | 3,287 | 50.14% | 3,275 | 49.31% | 1,583 | 48.98% | 1,348 | 46.72% | 1,401 | 47.24% | 16,666 | 47.06% |
| 70 and over | 1,208 | 18.56% | 1,372 | 20.70% | 1,424 | 21.72% | 1,722 | 25.93% | 948 | 29.33% | 915 | 31.72% | 1,003 | 33.82% | 8,592 | 24.26% |
| Morphology | ||||||||||||||||
| Squamous cell carcinoma | 1,765 | 27.12% | 1,768 | 26.67% | 1,772 | 27.03% | 1,754 | 26.41% | 840 | 25.99% | 738 | 25.58% | 768 | 25.89% | 9,405 | 26.56% |
| Adenocarcinoma | 3,087 | 47.44% | 3,143 | 47.42% | 3,114 | 47.50% | 3,251 | 48.95% | 1,620 | 50.12% | 1,470 | 50.95% | 1,515 | 51.08% | 17,200 | 48.57% |
| Small-cell carcinoma | 1,304 | 20.04% | 1,426 | 21.51% | 1,346 | 20.53% | 1,333 | 20.07% | 632 | 19.55% | 567 | 19.65% | 549 | 18.51% | 7,157 | 20.21% |
| Morphology not specified | 351 | 5.39% | 291 | 4.39% | 324 | 4.94% | 304 | 4.58% | 140 | 4.33% | 110 | 3.81% | 134 | 4.52% | 1,654 | 4.67% |
| Male | 4,153 | 4,066 | 4,023 | 4,010 | 1,816 | 1,687 | 1,702 | 21,457 | ||||||||
| Squamous cell carcinoma | 1,333 | 32.10% | 1,297 | 31.90% | 1,290 | 32.07% | 1,259 | 31.40% | 560 | 30.84% | 517 | 30.65% | 541 | 31.79% | 6,797 | 31.68% |
| Adenocarcinoma | 1,831 | 44.09% | 1,815 | 44.64% | 1,790 | 44.49% | 1,876 | 46.78% | 858 | 47.25% | 807 | 47.84% | 790 | 46.42% | 9,767 | 45.52% |
| Small-cell carcinoma | 773 | 18.61% | 770 | 18.94% | 725 | 18.02% | 700 | 17.46% | 319 | 17.57% | 306 | 18.14% | 295 | 17.33% | 3,888 | 18.12% |
| Morphology not specified | 216 | 5.20% | 184 | 4.53% | 218 | 5.42% | 175 | 4.36% | 79 | 4.35% | 57 | 3.38% | 76 | 4.47% | 1,005 | 4.68% |
| Female | 2,354 | 2,562 | 2,533 | 2,632 | 1,416 | 1,198 | 1,264 | 13,959 | ||||||||
| Squamous cell carcinoma | 432 | 18.35% | 471 | 18.38% | 482 | 19.03% | 495 | 18.81% | 280 | 19.77% | 221 | 18.45% | 227 | 17.96% | 2,608 | 18.68% |
| Adenocarcinoma | 1,256 | 53.36% | 1,328 | 51.83% | 1,324 | 52.27% | 1,375 | 52.24% | 762 | 53.81% | 663 | 55.34% | 725 | 57.36% | 7,433 | 53.25% |
| Small-cell carcinoma | 531 | 22.56% | 656 | 25.60% | 621 | 24.52% | 633 | 24.05% | 313 | 22.10% | 261 | 21.79% | 254 | 20.09% | 3,269 | 23.42% |
| Morphology not specified | 135 | 5.73% | 107 | 4.18% | 106 | 4.18% | 129 | 4.90% | 61 | 4.31% | 53 | 4.42% | 58 | 4.59% | 649 | 4.65% |
| Mean follow-up (months) | ||||||||||||||||
| Squamous cell carcinoma | 21.98 | Not evaluated | 22.00 | 21.38 | 20.15 | 15.63 | 9.91 | |||||||||
| Adenocarcinoma | 21.25 | Not evaluated | 20.67 | 19.86 | 18.43 | 15.36 | 10.01 | |||||||||
| Small-cell carcinoma | 17.96 | Not evaluated | 15.72 | 15.20 | 13.68 | 12.36 | 8.90 | |||||||||
LC, lung cancer; SACT, systemic anticancer therapy; SD, standard deviation.